Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Deeb

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|December 14, 2011
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphomaMatthew J Barth, Francisco J Hernandez-Ilizaliturri, Cory Mavis, et al.
Archives of Pathology & Laboratory Medicine|January 6, 2017
Multimodality Technologies in the Assessment of Hematolymphoid NeoplasmsShiyong Li, David L Jaye, Kyle T Bradley, et al.
Human Pathology|June 27, 2003
Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry studyDongfeng Tan, Qiang Li, George Deeb, et al.
Leukemia Research Reports|November 8, 2014
Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemiaKristin K Deeb, Matthew T Smonskey, HanChun DeFedericis, et al.
Leukemia & Lymphoma|December 1, 2012
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populationsJawad Francis, Avinash V Dharmadhikari, Sheila N J Sait, et al.
Leukemia Research|December 24, 2010
Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemiaGeorge Deeb, Mary M Vaughan, Ian McInnis, et al.
American Journal of Clinical Pathology|March 21, 2012
Monoallelic and biallelic deletions of 13q14.3 in chronic lymphocytic leukemia: FISH vs miRNA RT-qPCR detectionMatthew T Smonskey, AnneMarie W Block, George Deeb, et al.
Cancer Genetics and Cytogenetics|September 30, 2010
Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapseEunice S Wang, Sheila N J Sait, David Gold, et al.
Leukemia & Lymphoma|December 11, 2007
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphomaRaymond I Cruz, Francisco J Hernandez-Ilizaliturri, Scott Olejniczak, et al.
Anti-Cancer Drugs|September 3, 2013
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical modelsJuan J Gu, Francisco J Hernandez-Ilizaliturri, Cory Mavis, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|December 14, 2011
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphomaMatthew J Barth, Francisco J Hernandez-Ilizaliturri, Cory Mavis, et al.
Archives of Pathology & Laboratory Medicine|January 6, 2017
Multimodality Technologies in the Assessment of Hematolymphoid NeoplasmsShiyong Li, David L Jaye, Kyle T Bradley, et al.
Human Pathology|June 27, 2003
Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry studyDongfeng Tan, Qiang Li, George Deeb, et al.
Leukemia Research Reports|November 8, 2014
Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemiaKristin K Deeb, Matthew T Smonskey, HanChun DeFedericis, et al.
Leukemia & Lymphoma|December 1, 2012
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populationsJawad Francis, Avinash V Dharmadhikari, Sheila N J Sait, et al.
Leukemia Research|December 24, 2010
Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemiaGeorge Deeb, Mary M Vaughan, Ian McInnis, et al.
American Journal of Clinical Pathology|March 21, 2012
Monoallelic and biallelic deletions of 13q14.3 in chronic lymphocytic leukemia: FISH vs miRNA RT-qPCR detectionMatthew T Smonskey, AnneMarie W Block, George Deeb, et al.
Cancer Genetics and Cytogenetics|September 30, 2010
Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapseEunice S Wang, Sheila N J Sait, David Gold, et al.
Leukemia & Lymphoma|December 11, 2007
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphomaRaymond I Cruz, Francisco J Hernandez-Ilizaliturri, Scott Olejniczak, et al.
Anti-Cancer Drugs|September 3, 2013
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical modelsJuan J Gu, Francisco J Hernandez-Ilizaliturri, Cory Mavis, et al.
Pageof 6